STOK 8-K 2026-09-25
Stoke Therapeutics, Inc. (STOK) 8-K dated 2026-09-25 — accession 0001193125-26-402820.
Stoke Therapeutics, Inc. (STOK) is a biotechnology company listed on NASDAQ.
Stoke Therapeutics, Inc. filed a 8-K on 2026-09-25. Accession 0001193125-26-402820.
This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported STOK revenue for 2025-12-31 was $184.4M. Net income was -$6.9M. Revenue was up 404.5% from 2024-12-31 to 2025-12-31. STOK currently screens at market cap $1.88B.
Not investment advice. The STOK SEC hub lists recent forms. The stock page is the research view.